Mean cell count and SEM (n = 3) for SKBR3 cells treated for 72 hours with combinations of DMSO, 500 nM lapatinib, 500 uM capecitabine, and 50 ng/mL NRG1β or HGF. Lapatinib significantly decreased cell counts compared to DMSO (p=0.0067), and addition of ligand significantly increased cell count compared to lapatinib alone (p=0.0016). Capecitabine decreased cell count compared to DMSO (ns.), but addition of ligand did not significantly increase cell count compared to capecitabine alone. The combination of lapatinib and capecitabine significantly decreased cell counts compared to DMSO (p=0.0056) , and the addition of ligand significantly increased cell counts compared to combination (p=0.0012). Lapatinib plus ligand resulted in increased cell count compared to DMSO (ns). DMSO concentrations were matched to capecitabine concentrations. (Schindelin et al., 2012) Briefly, region of interest was selected with the center at the drug release point. Cropped image was transformed to 8bit and automatic thresholding was applied. Mean intensity was measured and averaged to generate the graphs (right). (b) Addition of HGF to Neratinib restored the proliferation to control levels, however, the differences were not significant as compared to the single agent. Quantification (left) and supporting images of Ki67 stained JIMT1 tumor sections in close proximity to the reservoirs are shown (right). (c) Basal levels of apoptosis were minor in BT474 xenograft model and thus the effect of different conditions was compared by evaluating the Ki67 signal only ( Figure 3E ). Values in the graph are means and SEM (n = 3); significance was calculated by a paired sample two-tailed t-test. hours with combinations of 500 nM lapatinib, 50 ng/mL NRG1β, 30 µg/mL pertuzumab, and 30 µg/mL trastuzumab. PBS, DMSO, and human IgG isotype control were used as controls for growth factors, lapatinib, and pertuzumab or trastuzumb, respectively. Lapatinib significantly decreased cell counts compared to DMSO (p<0.0001), and addition of ligand significantly increased cell count compared to lapatinib alone (p<0.0001)). Trastuzumab significantly decreased cell count compared to DMSO (p=0.0005). The combination of pertuzumab and NRG1β significantly increased cell count compared to NRG1β alone (p<0.0001). Addition of pertuzumab to lapatinib plus NRG1β significantly decreased cell counts compared to lapatinib plus NRG1β alone (p<0.0001), but addition of trastuzumab to lapatinib plus NRG1β did not.
